[Cardioprotective effects by XXXX after @entity63 and reperfusion in animal experiment studies].

@entity3372 @entity64 @entity296 @entity101 @entity35 @entity63 @entity4770 @entity842 @entity4346 @entity1812 @entity1811 @entity943
@entity1811 inhibitors induce an increase in kinin levels with subsequent release of @entity842 (NO) and @entity4770 , as shown in cultured endothelial cells and isolated @entity35 hearts. Isolated perfused working @entity35 hearts continuously release kinins and @entity4770 . During @entity63 after ligation of the left coronary artery kinin and @entity4770 concentrations in the venous effluent of the hearts are increased. @entity1811 inhibition with ramiprilat increases kinin concentrations during normoxia, @entity63 and reperfusion, whereas deendothelialization markedly reduces kinin and @entity4770 outflow in controls as well as in @entity1811 inhibitor-treated hearts. @entity35 hearts with postischemic reperfusion @entity943 are protected by ramiprilat- and @entity1812 perfusion, cardiodynamics and metabolism of treated hearts are improved. These effects are observed in concentrations too low to increase coronary flow. The cardioprotective effects of ramiprilat and @entity1812 are abolished by the specific B2-kinin receptor antagonist icatibant and by an inhibitor of NO-synthase. Long-term treatment (20 weeks) with @entity3372 in a blood-pressure-lowering dose (1 mg/kg/day) and a subantihypertensive dose (10 micromg/kg/day) protects spontaneously @entity101 @entity35 ( @entity64 prone) against @entity101 and @entity4346 in the high dose. In addition, both treatment regimens induce myocardial capillary growth. Isolated hearts of these animals show @entity296 and coronary flow, reduced release of cytosolic enzymes into the coronary effluent, and improved myocardial metabolism. These changes are observed even at a dose of @entity3372 which does not affect blood pressure and @entity4346 . They are abolished by chronic blockade of kinin receptors with icatibant.(ABSTRACT TRUNCATED AT 250 WORDS)
